Voxel in 2026: a Kraków operator of medical-imaging centres and radiopharmaceuticals, an mWIG40 issuer with a two-member management board

Voxel in 2026: a Kraków operator of medical-imaging centres, an mWIG40 issuer with a two-member management board, NFZ contracts as the revenue backbone

Voxel S.A. - headquartered at ul. Wielicka 265 in Kraków (postcode 30-663), registered in the KRS under number 0000238176 - is a Kraków operator of medical-imaging centre networks. Under the Voxel-Diagnostic brand, the company runs in Poland a network of several dozen clinics:

• Magnetic resonance imaging (MRI) - the most technologically advanced imaging examination, the dominant Voxel revenue segment.
• Computed tomography (CT) - the second main segment.
• X-ray (classical and digital), ultrasound, mammography - supporting examinations.
• Radiopharmaceuticals - production of isotopes for PET-CT examinations, in vertical integration.

The company has operated in its current legal form (joint-stock company under KRS 0000238176) since 2 August 2005, listed on the Warsaw exchange since November 2011 - as the first major Polish ticker in the medical-imaging sector. Corporate signature: Voxel's management board has just two members (CEO plus vice-president), making it one of the smallest boards in the mWIG40. Supervisory board: five members.

Voxel

KRAKÓW · KRS 0000238176 · SPÓŁKA AKCYJNA

Revenue

583.8 M PLN

Wielicka 265, Kraków: Kraków healthcare cluster

The address ul. Wielicka 265, 30-663 Kraków, places Voxel's seat in the south-eastern part of Kraków, on Wielicka street (the main route out of Kraków toward Wieliczka / Tarnów) - adjacent to the University Hospital and medical complexes. This is a strategically important location for a diagnostics company - proximity to large hospitals means proximity to patients referred by specialists for imaging examinations.

The company has a registered electronic-delivery address (ADE: PL-23931-31079-GCEDG-25) and a website at voxel.pl. Under Polish PKD codes the principal activity codes include 86 (human health activities) - including 8622 (specialist medical practice, which includes medical imaging) - and 21 (manufacture of basic pharmaceutical products, for the radiopharmaceutical segment).

Voxel operates under two complementary business models:

• B2C/B2B medical imaging - patients referred for examinations by specialist physicians. Payment: NFZ (public), private insurance (Medicover, LUX MED, Compensa), or directly from the patient.
• Radiopharmaceuticals for PET-CT - production of isotopes (mainly ⁹⁹ᵐTc-octreotydy, FDG) sold to other diagnostic centres. Voxel has its own PET-CT machines and vertically integrated radiopharmaceutical production.

Polish medical-imaging market: growing privatisation of segments

The Polish medical-imaging market on the Warsaw exchange has a narrowly represented structure - Voxel is practically the only large mWIG40 player purely in diagnostics. Off-exchange competitors:

• LUX MED - private medical group (controlled by British Bupa) with its own diagnostic clinics.
• Medicover - international medical group with Polish presence and own clinics.
• Affidea - private medical-imaging-centre network, controlled by a private-equity fund.
• Public NFZ diagnostics - hospitals, public institutions - most Polish MRI/CT examinations.

Three structural features of the Voxel model that explain its mWIG40 positioning:

• Structural demand for diagnostics - ageing of Polish society + development of precision medicine + rising incidence of civilisation diseases (cancer, neurological conditions) generates structurally growing demand for imaging examinations. This provides Voxel with a long-term revenue base.
• Cyclical exposure to NFZ tariffs - most Voxel revenue comes from contracts with the National Health Fund (NFZ). Every change in MRI/CT tariffs by the Ministry of Health directly affects group profitability. This makes the company regulatorily sensitive - even in a year of rising examination volumes, low tariffs may mean low margin.
• Capital-intensive model - a single MRI machine costs PLN 5–10 million, a PET-CT machine PLN 10–20 million. Voxel must regularly modernise equipment, requiring significant capex. This limits the room for high dividends and demands a long-term investment horizon.

Implication for the investment profile: stable demand, moderate dividend, regulatory exposure

“Voxel is a classic case of a Polish health-tech-services company - an operator of private diagnostic centres in a sector that grows structurally with the ageing of the Polish population. A minority investor here commits to exposure to the rising privatisation of the Polish healthcare sector, while bearing regulatory risk from NFZ tariffs and the capital intensity of equipment modernisation.”

Three expected consequences for the company's 2026 investment profile:

• Moderate dividend policy - Voxel has historically paid dividends in the PLN 0.80–2.50 per share range (yield 2–5%), positioning itself as a company with regular but not particularly generous payouts. The policy remains a function of balancing investment in new equipment with dividend distributions.
• Structural diagnostic demand in 2026 - in 2026 Poland continues the gradual privatisation of the healthcare sector, and population ageing (median age ~42) drives demand for imaging examinations. Voxel is a natural beneficiary.
• Key: NFZ decisions in 2026 - every change in NFZ MRI/CT tariffs in 2026 (expected in the second half of the year) is a meaningful event for the ticker's valuation. Tariff rises = margin improvement; cuts = profitability pressure.

For the Małopolskie voivodeship, Voxel is a smaller but specialty mWIG40 issuer of the region - Kraków as the regional capital has a clearly concentrated health-tech cluster (Voxel diagnostics, Mercator Medical disposables, Mabion biotech, Ryvu biotech), placing the region as one of Poland's leading health-tech hubs.

What you'll find in the Voxel profile

The Voxel S.A. profile in our database carries the full picture of the company: composition of the two-member management board (CEO plus vice-president - one of the smallest in the Polish mWIG40), the five-member supervisory board, the KRS registration history from 2 August 2005, the registered address at ul. Wielicka 265 in Kraków, e-delivery status (ADE PL-23931-31079-GCEDG-25), website voxel.pl, and the assigned PKD codes classifying the activity as health activities. The profile is also available in English - important for international health-fund investors, since Voxel is the only large Polish mWIG40 issuer in the medical-imaging segment.

Data: Polish KRS Court Register (KRS 0000238176); Voxel S.A. - annual reports 2023–2025; PKD classification 86/21 (health activities and pharmaceutical production); company history - founded 2005, S.A. 2005, WSE IPO November 2011; editorial estimates for the position in the Polish medical-imaging sector, as of 2026-05-02.